Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Clinical Trials in Russia:The Promise and the Approach

Since 1990, the number of clinical trials performed in Russia has grown rapidly, from 292 in 2002 to 563 in 2007. Russia’s large population and centralized health care system are two aspects of its environment that make Russia so conducive to clinical trials. Pharm-Olam’s “Clinical Trials in Russia, The Promise and the Approach ” Whitepaper details how to tap into the potential the Russian market has to offer.

The Whitepaper highlights:

  • The benefits of expanding your clinical trial pipeline into Russia.
  • The advantages that the Russian market offers
  • How to navigate the legislative & regulatory environment
  • The challenges of its regulatory process

Click the image to download the full whitepaper